前列腺癌大分割调强放疗联合同步整合推量的1/2期研究
这项1/2期前瞻性研究评估了基于风险的前列腺癌大分割同步整合推量调强放疗(HSIB-IMRT)的安全性和疗效,覆盖前列腺、精囊腺和盆腔淋巴结。2年医生报告的晚期2级以上泌尿和胃肠毒性累积发生率分别为32.6%和18.4%,但未缓解毒性较低;3年生化无复发生存率为96%。
要点
- HSIB-IMRT基于风险覆盖盆腔淋巴结,3年生化无复发生存率达96%。
- 2年医生报告晚期2级以上泌尿毒性累积发生率为32.6%,高于预期。
- 晚期胃肠和泌尿毒性相对短暂,末次随访未缓解2级以上泌尿毒性仅4.1%。
核心结论
- 基于风险淋巴结覆盖的HSIB-IMRT生化控制优异,但医生报告的泌尿毒性累积发生率高于预期,晚期胃肠和泌尿毒性相对短暂。
主要发现
- 2年医生报告的晚期2级以上泌尿和胃肠毒性累积发生率分别为32.6%和18.4%。
- 2年时仅10.2%的2级以上泌尿毒性和2.0%的2级以上胃肠毒性未缓解。
- 末次随访时医生报告的未缓解晚期2级以上泌尿和胃肠毒性发生率分别为4.1%和0%。
- 患者报告的AUA-IPSS中位数从基线10降至2年时7.5。
- 队列3年生化无复发生存率为96%。
关键数值与推荐
- 低危患者仅前列腺接受69.6 Gy分29次照射。
- 中危和高危患者接受30次照射,前列腺72 Gy、精囊腺54 Gy,当Roach公式预测淋巴结受累风险超过15%时盆腔淋巴结50.4 Gy。
- 中危和高危患者接受雄激素剥夺治疗。
临床怎么用
- HSIB-IMRT可基于风险覆盖前列腺、精囊腺和盆腔淋巴结,生化控制良好。
- 需关注医生报告的晚期泌尿毒性累积发生率较高,但多数毒性可缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluates the safety and efficacy of moderately hypofractionated radiation therapy (RT) with simultaneous integrated boost (HSIB) intensity modulated RT (IMRT) that includes coverage of the seminal vesicles (SVs) and pelvic lymph nodes (LNs). METHODS AND MATERIALS: Men with localized prostate cancer were prospectively enrolled in a phase 1/2 trial to receive HSIB-IMRT to the prostate, ± SV, ± pelvic LN using a risk-based method. Low-risk patients received 69.6 Gy to only the prostate in 29 fractions. Intermediate-risk (IR) and high-risk (HR) patients received 30 fractions with 72 Gy to the prostate, 54 Gy to the SV, and 50.4 Gy to the pelvic LN when risk of LN involvement exceeded 15% by the Roach formula. IR and HR patients received androgen deprivation therapy. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicity were prospectively evaluated with patient- and physician-reported surveys. RESULTS: Fifty-five men were enrolled, and 49 had at least 1 year of follow-up with 19.2% low-risk, 40.4% IR, and 40.4% HR disease. The median age was 69 years; median follow-up time was 36.9 months. Twenty-six patients received pelvic nodal HSIB-IMRT. At 2 years, the cumulative incidence of physician-reported late grade 2+ GU and GI toxicity was 32.6% and 18.4% respectively. At 2 years, only 10.2% grade 2+ GU toxicities and 2.0% grade 2+ GI toxicities remained unresolved. At last follow-up, the prevalence of unresolved physician-reported late grade 2+ GU and GI toxicity was 4.1% and 0%. The median patient-reported American Urologic Association-International Prostate Symptom Score fell from 10 at baseline to 7.5 at 2 years. The 3-year biochemical relapse-free survival rate for the cohort was 96%. CONCLUSIONS: HSIB-IMRT with risk-based nodal coverage results in excellent biochemical control. Although the cumulative incidence of physician-reported GU toxicity was higher than anticipated, late GI and GU toxicity was relatively transient.
引用
- Chang MG, Mukhopadhyay N, Holdford D, et al. Phase 1/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost. Pract Radiat Oncol. 2017. PMID: 29290572. doi:10.1016/j.prro.2017.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。